Cargando...
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
BACKGROUND: Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono‐ or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impa...
Gardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2012
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485963/ https://ncbi.nlm.nih.gov/pubmed/23152253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD008079.pub2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|